Cubist Systematic Strategies LLC Sells 194,604 Shares of Evolus, Inc. (NASDAQ:EOLS)

Cubist Systematic Strategies LLC cut its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 80.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,438 shares of the company's stock after selling 194,604 shares during the period. Cubist Systematic Strategies LLC owned about 0.07% of Evolus worth $524,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in Evolus by 63.5% in the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock valued at $2,753,000 after buying an additional 65,972 shares in the last quarter. KBC Group NV acquired a new position in shares of Evolus in the 4th quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Evolus by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after acquiring an additional 1,291 shares in the last quarter. Rhumbline Advisers grew its position in Evolus by 2.2% during the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company's stock worth $885,000 after acquiring an additional 1,762 shares during the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Evolus by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock valued at $368,000 after purchasing an additional 2,989 shares in the last quarter. 90.69% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. BTIG Research started coverage on Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 price objective on the stock. Barclays upped their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a research report on Thursday, April 10th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $23.75.

Insider Activity

In other news, insider Rui Avelar sold 27,904 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the transaction, the insider now directly owns 362,467 shares in the company, valued at approximately $4,806,312.42. This represents a 7.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Karah Herdman Parschauer sold 12,888 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now owns 32,183 shares in the company, valued at $418,057.17. This represents a 28.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 86,241 shares of company stock valued at $1,048,666. 5.90% of the stock is owned by insiders.

Evolus Stock Performance

Shares of EOLS stock traded down $0.18 on Wednesday, reaching $9.78. The stock had a trading volume of 72,166 shares, compared to its average volume of 687,115. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $630.51 million, a price-to-earnings ratio of -10.77 and a beta of 1.11. The firm's 50-day moving average is $11.19 and its two-hundred day moving average is $12.24.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.